Search results
Results from the WOW.Com Content Network
The typical seroconversion timecourse for hepatitis B. Seroconversion plays a major role in the diagnosis and treatment of hepatitis B infections. [60] As in other viral infections, seropositivity indicates that an individual has a sufficiently high concentration of antibody or antigen in the blood to be detectable by standard techniques.
Hepatitis B infection has been preventable by vaccination since 1982. [4] [12] As of 2022, the hepatitis B vaccine is between 98% and 100% effective in preventing infection. [1] The vaccine is administered in several doses; after an initial dose, two or three more vaccine doses are required at a later time for full effect. [1]
Liver function tests (LFTs or LFs), also referred to as a hepatic panel or liver panel, are groups of blood tests that provide information about the state of a patient's liver. [1] These tests include prothrombin time (PT/INR), activated partial thromboplastin time (aPTT), albumin , bilirubin (direct and indirect), and others.
The proportion of AST to ALT in hepatocytes is about 2.5:1, but because AST is removed from serum by the liver sinusoidal cells twice as quickly (serum half-life t 1/2 = 18 hr) compared to ALT (t 1/2 = 36 hr), so the resulting serum levels of AST and ALT are about equal in healthy individuals, resulting in a normal AST/ALT ratio around 1.
FibroTest, known as FibroSure in the US, is a biomarker test that uses the results of six blood serum tests to generate a score that is correlated with the degree of liver damage in people with a variety of liver diseases. FibroTest has the same prognostic value as a liver biopsy.
HBsAg (hepatitis B surface antigen) was the first hepatitis B virus protein to be discovered. [15] It consists of small (S), medium (M) and large (L) protein. [16] HBcAg (hepatitis B core antigen) is the main structural protein of HBV icosahedral nucleocapsid and it has function in replication of the virus. [17]
Possible causes for high ALT levels are liver inflammation (hepatitis A, B, C, infectious mononucleosis, acute viral fever, alcohol, pancreatic disorder), injury to muscles (trauma, myocardial infarction, congestive heart failure, acute kidney failure), and many toxins and drugs.
HBIG should be given within 14 days of exposure to the hepatitis B virus. [7] The half-life of HBIG is about 3 weeks. In lieu of a booster administration of HBIG, a hepatitis B vaccination is initiated at the time of the initial HBIG administration, thus providing long term protection.